DEFA14A: Zimmer Biomet to Acquire Paragon 28 in Definitive Agreement

Zimmer Biomet (ZB) and Paragon 28 have entered into a definitive agreement for ZB to acquire Paragon 28, aiming to expand ZB's presence in the foot and ankle segment.

Summary

• Zimmer Biomet (ZB) has agreed to acquire Paragon 28.
• The acquisition aims to combine Paragon 28's foot and ankle portfolio with Zimmer Biomet's global reach.
• The transaction is expected to close in the first half of 2025, pending regulatory and stockholder approvals.
• Paragon 28 stockholders will receive $13.00 per share in cash, plus a Contingent Value Right (CVR) potentially worth up to $1.00 per share based on milestone achievements.
• Vested and unvested equity awards will be cashed out, with accelerated vesting for unvested RSUs and PSUs.
• Albert DaCosta will continue to lead the Paragon 28 business within Zimmer Biomet.
• The Englewood, CO office will remain the hub for the Paragon 28 business.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the acquisition agreement, which provides value to stockholders and ensures continuity for the Paragon 28 business. The integration plans and future prospects are presented optimistically.

Positives

• The acquisition provides Paragon 28 with access to Zimmer Biomet's global footprint and resources.
• Stockholders will receive a cash payment of $13.00 per share, plus a potential CVR payment of up to $1.00 per share.
• Unvested equity awards will be accelerated, providing additional value to employees.
• Albert DaCosta will continue to lead the Paragon 28 business, ensuring continuity.
• The Englewood, CO office will remain the hub for the Paragon 28 business, minimizing disruption for local employees.

Negatives

• The ESPP will be terminated following the closing of the transaction.
• Employees will transition to Zimmer Biomet's compensation and benefits plans, which may result in changes.
• Some support functions may shift to align with corporate teams, potentially leading to adjustments in certain roles.
• Underwater stock options (grant price of $14.00 or more) will be canceled without any payout.

Risks

• The transaction is subject to regulatory and stockholder approvals, and may not close.
• Competing offers for Paragon 28 could emerge.
• The integration of the two businesses may not be successful.
• The revenue milestone necessary for the payment of the CVR may not be achieved.
• The transaction could disrupt business and operational relationships.
• The announcement or consummation of the transaction could negatively affect the market price of Paragon 28's stock.

Future Outlook

The transaction is expected to close in the first half of 2025, pending regulatory and stockholder approvals. The combined company aims to address unmet patient needs in the foot and ankle space.

Management Comments

• ZB understands that Paragon 28s exceptional people and products have made the company what it is today and are why ZB was attracted to this opportunity.
• Albert DaCosta will continue to lead the Paragon 28 business within the broader Zimmer Biomet organization.

Industry Context

This acquisition reflects a trend of consolidation in the medical technology industry, with larger companies seeking to expand their portfolios and market reach through strategic acquisitions. Zimmer Biomet's acquisition of Paragon 28 is aimed at strengthening its position in the rapidly growing foot and ankle segment.

Comparison to Industry Standards

• Zimmer Biomet's acquisition of Paragon 28 is similar to other acquisitions in the medical device industry, such as Stryker's acquisition of Wright Medical, which also focused on expanding its extremities portfolio.
• The $13.00 per share cash consideration, plus the CVR, is a standard deal structure in acquisitions of publicly traded companies, aiming to provide stockholders with both immediate value and potential future upside.
• The continuation of Albert DaCosta as the leader of the Paragon 28 business is a common practice in acquisitions, aimed at retaining key talent and ensuring a smooth transition.

Management Changes

Stakeholder Impact

• Stockholders will receive cash and a potential CVR payment.
• Employees will transition to Zimmer Biomet's structure and benefits.
• Customers and suppliers should expect continuity of service and support.
• The combined company aims to better address patient needs in the foot and ankle space.

Next Steps

• Obtain regulatory approvals.
• Obtain stockholder approval.
• Close the transaction in the first half of 2025.
• Form a joint integration team to plan and execute the transition.
• Transition employees to Zimmer Biomet's compensation and benefits plans.

Key Dates

Keywords

acquisition, Zimmer Biomet, Paragon 28, merger, foot and ankle, stockholders, CVR, equity, transaction, ESPP